Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GPCR |
---|---|---|
09:32 ET | 5613 | 37.96 |
09:34 ET | 3452 | 38.165 |
09:36 ET | 500 | 37.51 |
09:38 ET | 800 | 37.52 |
09:39 ET | 1300 | 37.72 |
09:41 ET | 1804 | 37.51 |
09:43 ET | 2809 | 37.6201 |
09:45 ET | 1611 | 38.045 |
09:48 ET | 5773 | 37.55 |
09:50 ET | 2167 | 37.87 |
09:52 ET | 500 | 37.88 |
09:54 ET | 4334 | 37.775 |
09:56 ET | 2167 | 38.07 |
09:57 ET | 1020 | 38.08 |
09:59 ET | 3165 | 37.96 |
10:01 ET | 2300 | 38.07 |
10:03 ET | 1467 | 38.11 |
10:06 ET | 3201 | 37.84 |
10:08 ET | 6218 | 37.78 |
10:10 ET | 400 | 37.65 |
10:12 ET | 1950 | 37.39 |
10:14 ET | 5601 | 37.525 |
10:15 ET | 6701 | 37.79 |
10:17 ET | 1037 | 37.7 |
10:19 ET | 2030 | 37.81 |
10:21 ET | 1800 | 37.75 |
10:24 ET | 3701 | 37.72 |
10:26 ET | 5574 | 37.68 |
10:28 ET | 1615 | 37.72 |
10:30 ET | 1550 | 37.55 |
10:32 ET | 3522 | 37.56 |
10:33 ET | 3301 | 37.58 |
10:35 ET | 700 | 37.69 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Structure Therapeutics Inc | 2.2B | -16.2x | --- |
Apogee Therapeutics Inc | 2.2B | -19.5x | --- |
Iovance Biotherapeutics Inc | 2.3B | -4.5x | --- |
CG Oncology Inc | 2.0B | -27.8x | --- |
Janux Therapeutics Inc | 2.1B | -33.6x | --- |
Rocket Pharmaceuticals Inc | 1.9B | -7.2x | --- |
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.32 |
Book Value | $9.76 |
P/E Ratio | -16.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.